MaxCyte Investor Presentation Deck

MaxCyte-Enabled Active Clinical Trials. Clinical Phase: Phase 1 Phase 1/2 Pivotal Commercial Cell Approach: Allogeneic Autologous Program received IND clearance but is not yet listed on clinicaltrials.gov As of March 2023/ Includes Commercial and Academic Clinical Trials CD34+/HSCS CB010 (Caribou Biosciences) CAR-T Trem-cel (Vor Biopharma) 13 EDIT301: B-thal (Editas Med) CASGEVYTM for SCD - UK/US B-thal - UK (Vertex Pharmaceuticals) APN401 (Invios GmbH) CASGEVYTM: B-thal in US (Vertex Pharmaceuticals) CD34+/HSCS EDIT301: SCD (Editas Med) Other Cell Types/ Approaches M MaxCyte © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation